Dr Burke on Challenges Associated With Initiating Venetoclax in Patients With CLL

John M. Burke, MD, hematologist, medical oncologist, Rocky Mountain Cancer Centers, Sarah Cannon Cancer Institute, discusses results from a United States community-based healthcare practitioner survey, highlighting best practices to overcoming challenges in initiating venetoclax (Venclexta) for patients with chronic lymphocytic leukemia. These findings were presented by Burke at the 2024 ASH Annual Meeting.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Chronic Lymphocytic Leukemia

 Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy. 

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


ASH Annual Meeting and Exposition

John M. Burke, MD, discusses results from a US community-based healthcare practitioner survey on challenges in initiating venetoclax for patients with CLL.